The original, highly specialized, polyphenol complex
invented by Dr. Jack Masquelier, now known as Flavay®,
works in various different ways to promote better health:
Flavay® is a powerfully effective antioxidant
that recycles other antioxidants in the body after they have
quenched corrosive free radicals which affect many tissues
and conditions including cognitive impairment and premature
aging.
Flavay® helps to regulate the good-bad free radical,
nitric oxide, which is essential
for: normal blood circulation, coordinating activity between
the immune system and the brain, and modulating communication
between brain cells—and is thereby deeply involved in
concentration, learning and memory.
Flavay® inhibits the release and synthesis of histamine,
a key factor in the promotion of inflammation;
reactions associated with conditions like vascular diseases,
allergies, and arthritis.
Flavay® strengthens and rebuilds collagen
proteins, improving skin and blood vessel health.
Flavay® is the product—used in the actual experiments—by
which Dr. Jack Masquelier established the "radical
scavenger effect." This incredible
compound from France has produced stunning health results across
Europe for more than 60 years.
Click the Links Below for Natural
& Healthy Support
of Your Body's Functions:
Statements made herein have not been
evaluated by the Food and Drug Administration. These products are not intended
to diagnose, treat, cure or prevent any disease.
Masquelier, J. A lifetime devoted to OPC and Pycnogenols. Alfa
Omega Editrice, Pub., 1996.
Schwitters, B., Masquelier, J. OPC in practice. Alfa Omega Editrice,
Publishers, 1995.
Kilham, C., Masquelier, J. OPC: The miracle antioxidant. Keats
Publishing, Inc., 1997.
Barilla, J. et al. The nutrition superbook: volume 1: the antioxidants.
Keats Publishing, Inc., 1995.
Facino RM, et al. Free radical scavenging action and anti-enzyme
activities of procyanidines from Vitis vinifera. A mechanism for
their capillary protective action. Arzneimittelforschung, 44:
592-601, 1994.
Kuttan R, et al. Collagen treated with catechin becomes resistant
to the action of mammalian collagenase. Experientia, 37: 221-223,
1981.
Masquelier, J., et al. Stabilization du collagene par les oligomeres
procyanidoliques. Acta Therapeutica, 7:101-105, 1981.
Masquelier, J. Aspects pharmacologiques nouveaux de certains flavonoides.
A Vie Medical 12:1969.
Laparra, J., et al. Etude pharmaco-cinetique des oligomers procyandoliques
totaux du raisin. Acta Therapeutica, 4, 1978.
Laparra, J., et al. Etude pharmacocinetique des oligomeres flavonoliques.
Plantes med et phyto, Tome XI, pp. 133-142, 1977.
Robert A.M.; Groult, N.; Six, C.; Robert, L. Etude de l’action
des oligomeres procyanidoliques sur des cellules mesenchymateuses
en culture. Ii l’attachment des fibres elastiques aux cellules.
(Study of the effect of procyanidolic oligomers on mesenchymal
cells in culture. Ii attachment of elastic fibers to the cells.)
Pat Biol, (30)6:601-7, 1990.
Porter, Lawrence J., Wong Rosalind Y. Chan, Bock G. The molecular
and crystal structure of (+)-2,3-trans-3,4-trans-leucocyanidin
[(2r,3s,+r)-(+)-3,3’, 4.4’, 5.7’-Hexahydroxyflavan]
dihydrate, and comparison of its heterocyclic ring conformation
in solution and the solid state. Journal of the Chemical Society;
Perkin Transactions I 1985. pp. 1413-17.
Masquelier, J. Proanthocyanidins et radicaux libres. 1985.
Uchida, S., et al. Condensed tannins scavenge active oxygen free
radicals. Med Sci Res, (15) 1987. pp. 831-832.
Ariga, T. Radical scavenging action and its mode in procyanidins
b-1 and b-3 from azuki beans to peroxyl radicals. Agric Biol Chem,
54(10) 1990. pp. 2499-2504.
Da Silva, R., et. al. Radical scavenger capacity of different
procyanidins from grape seeds. Presented at a symposium, “Free
radicals in biotechnology and medicine.” Royal Society Of
Chemistry, London January 1990, pp. 79-80.
Bauman, J., Wurm, G., Bruchhausen, F. “Hemmung der prostagladinsynthetase
durch flavonoide und phenolderivate im vergleich nit deren 02
radikalfangereigenschaften” Arch Pharm, (Weinheim) 313 (1980)
pp. 330-337.
Lombard, J., et al. The brain wellness plan. Kensington Pub. Corp.,
1998.
Flesch M., et al., Effects of red and white wine on endothelium-dependent
vasorelaxation of rat aorta and human coronary arteries. Am J
Physiol 1998;275:1183-94.
Fitzpatrick, D.F., Fleming R.C., Bing B, Maggi DA, O'Malley RM.
Isolation and characterization of endothelium-dependent vasorelaxing
compounds from grape seeds. J Agr & Food Chem In press.
Fitzpatrick, D.F., Maggi D, Bing B, Coffey RG. Vasorelaxation,
endothelium, and wine. BioFactors 1997;6:455-459.
Fitzpatrick, D.F., Hirschfield SL, Ricci T, Jantzen P, Coffey
RG. Endothelium-dependent vasorelaxation caused by various plant
extracts. J Cardiovasc Pharmacol 1995;26:90-95.
Fitzpatrick, D.F., Hirschfield SL, Coffey RG. Endothelium-dependent
vasorelaxing activity of wine and other grape products. Amer J
Physiol 1993;265:H774-H778.
Lincoln, J., Hoyle, C.H.V., Burnstock, G., Nitric oxide in health
and disease. Cambridge University Press, 1997.
Libby, P., Ridker, P.M., Maseri, A. Inflammation and atherosclerosis.
Circulation 2002 Mar 5; 105(9): 1135-43.
Lindahl, B. et al. Markers of myocardial damage and inflammation
in relation to long-term mortality in unstable coronary artery
disease. FRISC Study Group. Fragmin during Instability in Coronary
Artery Disease. N. Engl. J. Med. 2000 Oct 19; 343(16): 1139 47.
Mendall, M.A., et al. In the largest study of its kind published
to date, researchers report that hospitalized heart patients who
took antibiotics had a significantly lower risk of returning to
the hospital with severe chest pain within one year compared with
those on a placebo. Circulation: Journal of the American Heart
Association, Aug. 20, 2002.
Ridker, P.M., Cushman, M., Stampfer, M.J., Tracy, R.P., Hennekens,
C.H. Inflammation, aspirin, and the risk of cardiovascular disease
in apparently healthy men. N. Engl. J. Med. 1997 Apr 3; 336(14):
973-9.
Facino, R.M., et al. Free radical scavenging action and anti-enzyme
activities of procyanidines from vitis vinifera. A mechanism for
their capillary protective action. Arzneimittelforschung, 44:
592-601, 1994.
Kuttan, R., Donnelly, P.V., Di Ferrante, N. Collagen treated with
catechin becomes resistant to the action of mammalian collagenase.
Experientia, 37: 221-223, 1981.
Masquelier, J. Procyanidolic oligomers. J Parums Cosm Arom, 95:
89-97, 1990.
Tixier, J.M., et al. Evidence by in vivo and in vitro studies
that binding of pycnogenols to elastin affects its rate of degradation
by elastases. Biochem Pharmacol, 33: 3933-3939, 1984.
Kakegawa, H., et al. Chem. Pharm. Bull. 33:5079, 1985.
Harmand, M.F., Blanquet, P. The fate of total flavanolic oligomers
extracted from ‘vitus vinifera l.’ in the rat. European
Journal of Drug Metabolism and Pharmaccokinetics. 1978, No. 1
pp. 15-30.
Delrieu, P., Ding J., Escande, B., Samain, D. Free-radical scavenging
activity of proanthocyanidolic oligomers encapsulated in glycospheres:
an in vivo and in vitro study. Cosmetology Department & S
Biovectors, Ramonville St. Agne France. pp. 1-9.
Meunier, M.T., Villie, F., et al. Inhibition of angiotensin i
converting enzyme by flavanolic compounds: in vitro and in vivo
studies. Planta Medica, May 26, 1986. pp. 12-15.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques
chez l’animal-oedenme de la patte. Sanofi Res Toul Cedex
Fr, pp31-40.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques
chez l’animal-activite aniagoniste vis-a-vis des mediateurs
de l’inflamation. Sanofi Res Toul Cedex Fr, pp. 31-40.
Dubos, C., Durst, G., Hugonot, H. Evolution de la resistance capillaire,
spontanement ou artificiellement diminuee par l’action d’une
substance capillaro-toxique chez des personnes agees--action benefique
d’un agnet actif sur la micro-circulation: l’Endotelon.
Inform. Therapeut. 1980. pp. 302-305.
Dartenuc, J.Y., et al. Resistance capillaire en geriatrie etude
d’un microangioprotecteur-Endotelon. Bordeaux Med. 13:903-7,
1990.
Lagrue, G., Olivier-Martin, F., Grillot, A. “Etude des effets
des oligomeres du procyanidol sur las resistance capillaire dand
l’hypertension arterielle et certaines nephropathies.”
Sen. Hosp. Paris 18-25 Septembre, 1981.
Beylot, C., Bioulac, P. Essai therapeutique d’un angioprotecteur
peripherique, l’Endotelon. Actualite Therapeutique Gaz. Med.
de France (87)22:2919-24, 1980.
Lesbre, F.X., Tigaud, J.D. Effect de l’Endotelon sur l’indice
de fragilite capillaire dan une population specifique: les sujets
cirrhotiques. Gaz. Med. de France, (90)24 1983.
Sarrat, L. Abord therapeutique des troubles fonctionnels des membres
inferieurs par un microangioprotecteur l’Endotelon. Bordeaux
Med, 11:685-8, 1981.
Delacroix, P. Etude en double aveugle de l’Endotelon dans
l’insuffisance veineuse chronique. Therapeutique, la Revue
de Medicine, (27-28) Sept. 1981. pp. 1793-1802.
Thebaut, J.F, Thebaut, P., Vin, F. Etude de l’Endotelon dand
les manifestations fonctionnelles de l’insuffisance veineuse
peripherique-resultats d’une etude en double aveugle portant
sur 92 patients.” Gazette Medicale, (92)1, 1985. pp. 96-100.
Chang, W.C., Hsu, F.L. Inhibition of platelet aggregation and
arachidonate metabolism in platelets by procyanidins. Prostagland
Leukotri Essent Fatty Acids, 38:181-8, 1989.
Masquelier, J. Pycnogenols: recent advances in the therapeutical
activity of procyanidins. Supplement of Planta Medica, Journal
of Medicinal Plant Research and Journal of Natural Products, July
1980 pp. 243-256.
Henning, B., et al. Lipid peroxidation and endothelial cell injury:
implications in atherosclerosis. Free Rad Path & Med, (4)1988
pp. 99-106.
Masquelier, J. “Les procyanidols du vin leur role dans l’alcoolisme.”
pp. 88-93.
Gazave, J.M. “Notions recentes sur les capillaires”
unpub. bulletin from the Laboratoire De Physiologie Patholigie
pp. 26-29.
Ruf, J.C. Wine and polyphenols related to platelet aggregation
and atherothrombosis. Office International Vigne et du Vin, Nutrition
and Health Unit, Paris France; Drugs under Experimental and Clinical
Research (Switz.) 25/2-3 (125-131), 1999.
Blaszo, G. Gabor, M. Oedema-inhibiting effect of procyanidin.
Acta Physiologica Academiae Scientiarum Hungaricae, Tomus 56(2):235-240,
1980.
Tayau, M.F, LeFevre, G. Action du leucocyanidol sur l’hyalaluronidase.
Bull Soc Pharm Bordeaux, 95:132-136, 1956.
Lamy, M. Utilization des oligomeres procyanidoliques en gynecologie.
Essai Therapeutique Tomel (14) Sept. 2, 1981. pp. 1021-22.
Henriet, J.P “Une Etude Exemplaire Pour Un Phlebotrope: l’etude
EIVE.’ Unpub., pp. 77-83.
Pfister, A., Simon, M.T., Gazave, J.M. Sites de fixation des oligomeres
procyanidoliques dans la paroi des capillaires sanguins du poumon
decobaye. Acta Therapeutica (8) 1982. pp. 223-237.
Kuttan, R., Donnelly, P., Di Ferrante, N. “Collagen treated
with (+) -catechin becomes resistant to the action of mammalian
collagenase.” Laboratory of Connective Tissue Research, Dept.
of Biochem. Baylor Col. of Med., Houston TX. 28, May, 1980.
Gendre, P., Laparra, J., Barraud, E. “Effect protecteur des
oligomeres procyanidoliques sur le lathyrisme experimental chez
le rat.” Ann. Pharm. Francaises, (43)1, 1985 pp. 61-73.
Corbe, C., Boissin, J.P., Siou, A. Light vision and chorioretinal
circulation. Study of the effect of procyanidolic oligomer (Endotelon).
Jn. Fr. Opthalmol, (11)5:453-460, 1988.
Boissin, J.P., Corbe C., Siou, A. Chorioretinal circulation and
dazzling: use of procyanidol oligomers (Endotelon). Bull Soc Ophtalmol
Fr, 88(2):173-4, 177-9, 1988.
Proto, F. et al. Electrophysical study of vitis vinifera procyanoside
oligomers effects on retinal function in myopic subjects. Ann
Ott Clin Ocul, 114:85-93, 1988.
Saracco, J.B., Estachy, G.M. Etude d l’Endotelon en opthalmologie.
Gaz Med de France, 88:2035-2038, 1981.
Scharrer, A., Ober, M. Anthocyanosides in the treatment of retinopathies.
Klin Monatsbl Augenheilkd, 178:386-389, 1981.
Corbe, C., et al. Microangiopathy of the retina. J. Fr. Opthalmol,
11:453, 1988.
Verin, M.M., Vildy, A., Maurin, J.F., Retinopathies et O.P.C.
Bordeaux Medicale, (16)11. pp. 1467-74, 1978.
Soyeux, A. et al. Endotelon. Diabetic retinopathy and hemorheology.
Bull Soc Ophtalmol Fr. 87(12):1441-4, 1987.
Fromantin, M. “Les oligomeres procyanidoliques dans le traitement
de la fragilite capillaire et de la retinopathie chez les diabetiques.
A propos de 26 cas.” Med Int, 16(11):432-434, Nov. 1981.
Arne, J.L. Contribution a l’etude des oligomeres procyanidoliques:
Endotelon, dans la retinopathie diabetique (a propos de 30 observations).
Gaz. Med. de France, Vol. 89, No. 30, Oct. 8, 1982.
Baruch, J. Effect of Endotelon in postoperative edema. Results
of a double-blind study versus placebo in 32 female patients.
Ann Chir Plast Esthet 29(4):393-5, 1984.
Rao, C.N. et al. Influence of bioflavonoids on the collagen metabolism
in rats with adjuvantinduced arthritis. Ital J Biochem. 30:54-62,
1981.
Gabor, M. Pharmacologic effects of flavonoids on blood vessels.
Angiologica, 9:355-374, 1972.
Havsteen, B. Flavonoids, a class of natural products of high pharmacological
potency. Biochem Pharmacol, 32:1141-48, 1983.
Reimann, H.J., Lorenz, W., Fischer, M., Frölich, R., Meyer,
H.J. Berkhauser Verlag, Vol. 7/1, Univ. of Marburg/Lahn, Ger.,
1977.
Masquelier, J. Action protectrice du vin sur l’ulcere gastrique.
Resultats, p. 61.
Amella, M., et al. Inhibition of mast cell histamine release by
flavonoids and bioflavonoids. Planta Medica, 5116-20, 1985.
Packer, L., et al. The antioxidant miracle: your complete plan.
John Wiley & Sons, Inc., 1999.
Shaw, R. How [Australian] PycnoGenol [MASQUELIER’s®]
Helps Sports People.
Masquelier, J. Procyanidolic oligomers (leucocyanidins). Parfums
Cosmet Arom 95:89-97, 1990.
Pecking, A., Desprez-Curely, J.P., Megret, G. Oligomers procyanidoliques
(Endotelon) dans le traitement des lymphoedemes post-therepeutiques
de members superieurs. Symposium Satellite, Congres International
d’Angiologie, Toulouse, France, 4-7 Oct. 1989.
Fahey, T.D., Pearl M. Hormonal effects of phosphatidylserine during
2 weeks of intense training. Abstract submitted to national meeting
of the Amer College of Sports Medicine, June 1998.
Monteleone, P., Maj, M., Beinat, L., Natale, M., Kemali, D. Blunting
by chronic phosphatidylserine administration of the stress-induced
activation of the hypothalamo-pituitary-adrenal axis in healthy
men. Eur J Clin Pharm 43: 385–388, 1992.
Fahey, T.D., et al. The hormonal and perceptive effects of phosphatidylserine
administration during two weeks of resistive exercise-induced
overtraining. Bio of Sport 15(3):135-44, 1998.
Laparra, J., Michaud, J. Masquelier, J. Action des oligomeres
procyanidoliques sur le cobaye carence en vitamin c. Tavaux Originaux,
University of Bordeaux, 1976.
Masquelier, J. Action comparee de divers facteurs vitaminiques
p sur l’oxydation de l’acide ascorbique par les ions
cuivriques. Bull. de la Societe de Chimie Biologique XXXIII (3-4)
1951. pp. 302-304.
Masquelier, J. Action comparee de divers facteurs vitaminiques
p sur l’acide ascorbique-oxydase. Bull. de la Societe de
Chimie Biologique XXXIII (3,4) 1951. pp.304-306
Kakegawa, H., Matsumoto, H., Endo, K., Satoh, T., Nonaka, G.,
Mishioka, I. “Inhibitory effects of tannins on hyaluronidase
activation and on the degranulation from rat mesentery mast cells.”
Chem. Pharm. Bull. 33(11)1985. 5079-5082.
Reiman, H.J., Lorenz, M., Fischer, R., Frolich, H., Meyer, J.
“Histamine and acute haemorrhagic lesions in rat gastric
mucosa: prevention of stress ulcer formulation by (+)-catechin,
an inhibitor of specific histidine decarboxylase in vitro.”
Dirkhauser Verlag,Vol. 7/1, 1977.
Pariente, J.J. Parientl-Amsellem, J. “Les oedemes post-traumatoqies
chez le sportif: essai controle de l’Endothelon.” Actualite
Therapeutique 90(3) 2/11 1983 pp. 231-235.
Masquelier, J., et al. “Flavonoids et Pycnogenols” Int
J Vit Nut Res, (49)3:307-311, 1979.
Dumon, M., Michaud, J., Masquelier, J. Proanthocyanidin content
in vegetable extracts to be used in the preparation of medicines.
Bull. Soc. Pharm. Bordeaux, 129:51-65, 1990.
